Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Kathryn Ball, Simon J. Dovedi, Pavan Vajjah, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 32
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
Michael T. Lotze, Scott H. Olejniczak, Dimitris Skokos
Nature reviews. Immunology (2024) Vol. 24, Iss. 12, pp. 878-895
Closed Access | Times Cited: 15
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Jacob Sands, Stéphane Champiat, H.-D. Hummel, et al.
Cancer (2025) Vol. 131, Iss. 3
Open Access | Times Cited: 1
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
John D. Davis, Marçal Bravo Padros, Daniela J. Conrado, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 3, pp. 422-439
Open Access | Times Cited: 22
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
Mohamed H. Omer, Areez Shafqat, Omar Ahmad, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4550-4550
Open Access | Times Cited: 17
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
KyoungSoo Lim, Xu Zhu, Diansong Zhou, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 2, pp. 315-327
Open Access | Times Cited: 8
Teclistamab: Mechanism of action, clinical, and translational science
Yue Guo, Natalia A. Quijano Cardé, Lijuan Kang, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 7
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, O. Hall, Jérémy Berret, et al.
Nature Cancer (2024)
Open Access | Times Cited: 6
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Timothy Qi, Xiaozhi Liao, Yanguang Cao
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 12, pp. 880-890
Open Access | Times Cited: 14
Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents
Lola Boutin, Clément Barjon, M Chauvet, et al.
European Journal of Immunology (2024) Vol. 54, Iss. 8
Open Access | Times Cited: 5
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology
Mohamed Elmeliegy, Joseph Chen, Aruna Dontabhaktuni, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 637-646
Open Access | Times Cited: 4
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies
Apolline Lefèvre, Zinnia P. Parra‐Guillén, Iñaki F. Trocóniz, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Unveiling the orchestration of T-cell dynamics: A comprehensive examination of their crucial role in revolutionizing immunotherapy for pancreatic and colon cancers
Sridevi Mardham, Soumya Dakshinamurthy
Elsevier eBooks (2025), pp. 199-232
Closed Access
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database
Xiangyang Le, Yefu Zhang, Junlong Ma
Expert Opinion on Drug Safety (2025)
Closed Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy
M. Tommy Gambles, Isaac Kendell, Jiahui Li, et al.
Nanomedicine Nanotechnology Biology and Medicine (2025), pp. 102825-102825
Closed Access
Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis
Pooneh Soltantabar, Sheena Sharma, Diane Wang, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 115, Iss. 6, pp. 1258-1268
Open Access | Times Cited: 3
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, María Vieito, Jorge Ramón, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 3
Natural killer cell engagers for cancer immunotherapy
Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi
Frontiers in Oncology (2025) Vol. 14
Open Access
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
Katy A. Lloyd, Jim Middelburg, Vitalijs Ovcinnikovs, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Targeted Oncology (2025)
Open Access
T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead
Tarek M. Taha, Kira‐Lee Koster, Johann S. de Bono
European Urology (2025)
Closed Access
Page 1 - Next Page

Scroll to top